PFIZER INC · News & developments
Pfizer’s Cheap Valuation Meets a Looming Patent Cliff
Source: Seeking AlphaBearish
The headline highlights a patent cliff as a material issue for Pfizer and frames it against the company’s valuation. It does not identify the affected products, expiry dates, revenue exposure, or mitigation measures.
Why this matters
Loss of exclusivity can reduce product revenue, gross margin, operating cash flow, and the funds available for dividends or debt reduction. Without product-level exposure and timing, the risk is clearly relevant to the prior fair value of $29 but cannot be incorporated more precisely.